(PAVE) A Nanovaccine Approach for the Treatment of Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in men and women and still fatal in over 90% of patients. It is characterised by its extremely aggressive nature where it is also responsible for the highest mortality rate compared to other major cancers, resulting in excess of 250,000 deaths worldwide per annum. Current state-of-art therapies for advanced PDAC including chemo- and/or radiotherapy, despite extensive efforts, have met with only limited success. New approaches, such as immunotherapy, are therefore needed where it has already shown promise in overcoming many aspects of this resistance. Immunotherapy has the potential to treat minimal residual disease after pancreatic resection (surgery) as well as for metastatic and non-resectable PDAC.
Our objective for this project is to bring together a multidisciplinary and intersectoral group to develop novel vaccine approaches, including use of multiple immunomodulating components.
More detailed information
Prof. Dr. Clemens Löwik
Role Erasmus MC:
Marie Sklodowska Curie ITN